174 related articles for article (PubMed ID: 25033809)
21. Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Guan Y; Zhang Y; Xiao L; Li J; Wang JP; Chordia MD; Liu ZQ; Chung LW; Yue W; Pan D
Mol Pharm; 2017 Jan; 14(1):1-13. PubMed ID: 26992462
[TBL] [Abstract][Full Text] [Related]
22. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
23. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
24. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Nevo Y; Aga-Mizrachi S; Elmakayes E; Yanay N; Ettinger K; Elbaz M; Brunschwig Z; Dadush O; Elad-Sfadia G; Haklai R; Kloog Y; Chapman J; Reif S
PLoS One; 2011 Mar; 6(3):e18049. PubMed ID: 21445359
[TBL] [Abstract][Full Text] [Related]
25. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat.
Pando R; Barshack I; Raz A; Luboshits G; Haklai R; Maysel-Auslender S; Kloog Y; Keren G; George J
Cardiovasc Pathol; 2010; 19(2):94-101. PubMed ID: 19144546
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Ling Y; Wang Z; Zhu H; Wang X; Zhang W; Wang X; Chen L; Huang Z; Zhang Y
Bioorg Med Chem; 2014 Jan; 22(1):374-80. PubMed ID: 24300920
[TBL] [Abstract][Full Text] [Related]
28. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
29. Salirasib in the treatment of pancreatic cancer.
Bustinza-Linares E; Kurzrock R; Tsimberidou AM
Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
[TBL] [Abstract][Full Text] [Related]
30. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
[TBL] [Abstract][Full Text] [Related]
31. Ras inhibition enhances autophagy, which partially protects cells from death.
Schmukler E; Grinboim E; Schokoroy S; Amir A; Wolfson E; Kloog Y; Pinkas-Kramarski R
Oncotarget; 2013 Jan; 4(1):145-55. PubMed ID: 23370967
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W
Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839
[TBL] [Abstract][Full Text] [Related]
33. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
34. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
George J; Sack J; Barshack I; Keren P; Goldberg I; Haklai R; Elad-Sfadia G; Kloog Y; Keren G
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):363-8. PubMed ID: 14670932
[TBL] [Abstract][Full Text] [Related]
36. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor.
Mor A; Haklai R; Ben-Moshe O; Mekori YA; Kloog Y
J Invest Dermatol; 2011 Oct; 131(10):2040-8. PubMed ID: 21716322
[TBL] [Abstract][Full Text] [Related]
38. Dislodgment and accelerated degradation of Ras.
Haklai R; Weisz MG; Elad G; Paz A; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochemistry; 1998 Feb; 37(5):1306-14. PubMed ID: 9477957
[TBL] [Abstract][Full Text] [Related]
39. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM
J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318
[TBL] [Abstract][Full Text] [Related]
40. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
